215 related articles for article (PubMed ID: 38509595)
21. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Distler O; Highland KB; Gahlemann M; Azuma A; Fischer A; Mayes MD; Raghu G; Sauter W; Girard M; Alves M; Clerisme-Beaty E; Stowasser S; Tetzlaff K; Kuwana M; Maher TM;
N Engl J Med; 2019 Jun; 380(26):2518-2528. PubMed ID: 31112379
[TBL] [Abstract][Full Text] [Related]
22. Systemic Sclerosis Associated Interstitial Lung Disease and Nintedanib: A Rare Disease and a Promising Drug.
Kafle S; Thapa Magar M; Patel P; Poudel A; Cancarevic I
Cureus; 2021 Jul; 13(7):e16404. PubMed ID: 34414042
[TBL] [Abstract][Full Text] [Related]
23. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™).
Distler O; Brown KK; Distler JHW; Assassi S; Maher TM; Cottin V; Varga J; Coeck C; Gahlemann M; Sauter W; Schmidt H; Highland KB;
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):75-81. PubMed ID: 28664834
[TBL] [Abstract][Full Text] [Related]
24. Elevated Fibronectin Levels in Profibrotic CD14
Rudnik M; Hukara A; Kocherova I; Jordan S; Schniering J; Milleret V; Ehrbar M; Klingel K; Feghali-Bostwick C; Distler O; Błyszczuk P; Kania G
Front Immunol; 2021; 12():642891. PubMed ID: 34504485
[TBL] [Abstract][Full Text] [Related]
25. Distinct Properties of Human M-CSF and GM-CSF Monocyte-Derived Macrophages to Simulate Pathological Lung Conditions In Vitro: Application to Systemic and Inflammatory Disorders with Pulmonary Involvement.
Lescoat A; Ballerie A; Augagneur Y; Morzadec C; Vernhet L; Fardel O; Jégo P; Jouneau S; Lecureur V
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562615
[TBL] [Abstract][Full Text] [Related]
26. Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.
Kuwana M; Allanore Y; Denton CP; Distler JHW; Steen V; Khanna D; Matucci-Cerinic M; Mayes MD; Volkmann ER; Miede C; Gahlemann M; Quaresma M; Alves M; Distler O
Arthritis Rheumatol; 2022 Mar; 74(3):518-526. PubMed ID: 34514739
[TBL] [Abstract][Full Text] [Related]
27. Myeloid cell-specific deletion of Capns1 prevents macrophage polarization toward the M1 phenotype and reduces interstitial lung disease in the bleomycin model of systemic sclerosis.
Zhang L; Zheng D; Yan Y; Yu Y; Chen R; Li Z; Greer PA; Peng T; Wang Q
Arthritis Res Ther; 2022 Jun; 24(1):148. PubMed ID: 35729674
[TBL] [Abstract][Full Text] [Related]
28. Endothelial Cells Expressing Endothelial and Mesenchymal Cell Gene Products in Lung Tissue From Patients With Systemic Sclerosis-Associated Interstitial Lung Disease.
Mendoza FA; Piera-Velazquez S; Farber JL; Feghali-Bostwick C; Jiménez SA
Arthritis Rheumatol; 2016 Jan; 68(1):210-7. PubMed ID: 26360820
[TBL] [Abstract][Full Text] [Related]
29. Nintedanib Therapy Alone and Combined with Mycophenolate in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: Systematic Reviews and Meta-analysis.
Herman D; Ghazipura M; Barnes H; Macrea M; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
Ann Am Thorac Soc; 2024 Mar; 21(3):474-485. PubMed ID: 37773000
[No Abstract] [Full Text] [Related]
30. [How do I treat interstitial lung disease in systemic sclerosis?].
Riemekasten G
Z Rheumatol; 2021 Feb; 80(1):69-72. PubMed ID: 33340058
[TBL] [Abstract][Full Text] [Related]
31. Real life data on nintedanib safety: idiopathic pulmonary fibrosis versus systemic sclerosis-interstitial lung disease and strategies adopted to manage adverse effects.
Di Battista M; Tavanti L; Pistelli F; Carrozzi L; Da Rio M; Rossi A; Puccetti L; Tavoni A; Romei C; Morganti R; Della Rossa A; Mosca M
Inflammopharmacology; 2023 Oct; 31(5):2445-2449. PubMed ID: 37535212
[TBL] [Abstract][Full Text] [Related]
32. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
Front Immunol; 2020; 11():1990. PubMed ID: 33013852
[TBL] [Abstract][Full Text] [Related]
33. Systemic sclerosis with associated interstitial lung disease: management considerations and future directions.
Bernstein EJ; Huggins JT; Hummers LK; Owens GM
Am J Manag Care; 2021 May; 27(7 Suppl):S138-S146. PubMed ID: 34003617
[TBL] [Abstract][Full Text] [Related]
34. Periostin-An inducer of pro-fibrotic phenotype in monocytes and monocyte-derived macrophages in systemic sclerosis.
Suzuki M; Ototake Y; Akita A; Asami M; Ikeda N; Watanabe T; Kanaoka M; Yamaguchi Y
PLoS One; 2023; 18(8):e0281881. PubMed ID: 37531393
[TBL] [Abstract][Full Text] [Related]
35. A Drug-Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease.
Vonk MC; Guillén-Del-Castillo A; Kreuter M; Avis M; Marzin K; Mack SR; Wind S; Gahlemann M
Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):81-89. PubMed ID: 34664183
[TBL] [Abstract][Full Text] [Related]
36. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Magnusson MO; Freiwald M
Respir Med; 2021; 180():106369. PubMed ID: 33798871
[TBL] [Abstract][Full Text] [Related]
37. Beneficial effects of nintedanib on cardiomyopathy in patients with systemic sclerosis: a pilot study.
Ninagawa K; Kato M; Tsuneta S; Ishizaka S; Ujiie H; Hisada R; Kono M; Fujieda Y; Ito YM; Atsumi T
Rheumatology (Oxford); 2023 Jul; 62(7):2550-2555. PubMed ID: 36458921
[TBL] [Abstract][Full Text] [Related]
38. Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis.
Khanna SA; Nance JW; Suliman SA
Curr Rheumatol Rep; 2022 May; 24(5):166-173. PubMed ID: 35499699
[TBL] [Abstract][Full Text] [Related]
39. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.
Rahaghi FF; Hsu VM; Kaner RJ; Mayes MD; Rosas IO; Saggar R; Steen VD; Strek ME; Bernstein EJ; Bhatt N; Castelino FV; Chung L; Domsic RT; Flaherty KR; Gupta N; Kahaleh B; Martinez FJ; Morrow LE; Moua T; Patel N; Shlobin OA; Southern BD; Volkmann ER; Khanna D
Respir Res; 2023 Jan; 24(1):6. PubMed ID: 36624431
[TBL] [Abstract][Full Text] [Related]
40. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Sarr C; Freiwald M
BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
